Pancreatic Cancer

INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.

Daraxonrasib plus vopimetostat demonstrated a favorable RAS-associated safety profile in patients with MTAP-deleted, pretreated metastatic pancreatic ductal adenocarcinoma.

Atebimetinib plus modified gemcitabine/nab-paclitaxel demonstrated an ORR of 36% and median OS of 17.3 months in first-line metastatic pancreatic cancer.

Daraxonrasib yielded a 13.2 month OS vs 6.6 months with chemotherapy for patients with metastatic PDAC.

Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC.

Mohamed Adam, MD, discusses switching from open to robotic Whipple procedures and the impending integration of AI-driven navigation in surgical oncology.

Philip Blumenfeld, MD, discussed the feasibility of radium 224 Alpha DaRT sources delivered via endoscopic ultrasound for patients with pancreatic cancer.

The FDA issued a “safe to proceed” letter for an expanded access program for daraxonrasib in metastatic pancreatic ductal adenocarcinoma.

According to Asfar Azmi, PhD, results from the study showed that the PCNA inhibitor AOH1996 was synergistic with KRAS inhibitors of all classes.

Asfar Azmi, PhD, discussed a poster from the AACR Annual Meeting that investigated the NAMPT inhibitor RPT-E-037 and the pan-RAS inhibitor daraxonrasib in pancreatic cancer.

Data from a phase 1 trial suggest that durable, vaccine-induced T-cell memory may be achievable even in pancreatic ductal adenocarcinoma.

The FDA has granted fast track designation to BBO-11818, an investigational pan-KRAS inhibitor, for advanced KRAS-mutant pancreatic ductal adenocarcinoma.

Diane Simeone, MD, discussed efficacy results from the phase 3 RASolute 302 trial evaluating daraxonrasib in patients with metastatic pancreatic cancer.

Results from the phase 3 RASolute 302 trial showed that daraxonrasib improved median OS compared with standard chemotherapy in metastatic PDAC.

Integrating a medically supervised ketogenic diet with gemcitabine, nab-paclitaxel, and cisplatin significantly extends OS in those with metastatic PDAC.

Sebnem Ece Eksi, PhD, discussed how sympathetic signaling drives CAF activation and tissue remodeling to support tumor progression in pancreatic cancer.

Namodenoson did not exhibit any new safety signals or unexpected toxicity as a treatment for patients with PDAC who progressed on at least 1 systemic therapy.

Neoadjuvant mFOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma demonstrated a 100% R0 resection rate.

Neoadjuvant therapy improves survival for patients with upfront resectable pancreatic cancer and minor PMV abutment vs an upfront surgical approach.

Diane Simeone, MD, detailed how the PRECEDE Consortium utilizes standardized data sharing and high-risk screening to identify stage I pancreatic cancer.

Diane Simeone, MD, highlights the necessity of a collaborative approach to pancreatic cancer screening, similar to trends across multiple disease states.

The PRECEDE Consortium is a multidisciplinary effort to drive the earlier detection of pancreatic cancer and raise the survival rate to 50%.

PANOVA-3 findings demonstrated that patients with previously untreated pancreatic cancer experienced better outcomes when adding TTFields to chemotherapy.